Mechanistic Exploration of cGAS-STING-Mediated Vaccine Enhancement
cGAS-STING 介导的疫苗增强机制探索
基本信息
- 批准号:10318966
- 负责人:
- 金额:$ 78.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-23 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAgonistAnimal ModelAntigen-Presenting CellsAntigensBiologicalBiologyCRISPR/Cas technologyCategoriesCell LineCell NucleusCell physiologyCellsChemicalsChemosensitizationClinicalClustered Regularly Interspaced Short Palindromic RepeatsCyclic GMPDetectionDinucleoside PhosphatesDissectionEnzymesEvaluationExhibitsExperimental ModelsFormulationGene ActivationGenesGeneticGenetic TranscriptionGoalsHumanIRF3 geneImmuneImmune responseImmune systemImmunityImmunizationImmunologicsImmunotherapeutic agentIn VitroInfectionInnate Immune ResponseLigandsLinkLymphoid CellMacaca mulattaMediatingMessenger RNAMicrobeMitochondriaModelingMolecularMusMyeloid CellsNuclearOntologyOutcomePathway interactionsPatternPattern recognition receptorPenetrationPeriodicityPharmacologyPhenotypePhysiological ProcessesPrimatesProcessProteinsResearchRoleSignal TransductionSignaling ProteinSolubilityStimulator of Interferon GenesStromal CellsSystemT-LymphocyteTechnologyTestingTissuesTranscriptTranslatingVaccinationVaccine AdjuvantVaccinesViral AntigensZika Virusadaptive immune responseadaptive immunityanalogbasecell typeclinically relevantds-DNAgene functionhuman modelimmunogenicimmunogenicityimmunoregulationin vivoinnate immune functioninsightmicrobialmonocytemouse modelnonhuman primatenovelpathogenpathogenic microberecruitresponsesmall moleculetooltranscription factortranscriptomicsvaccination outcomevaccine efficacy
项目摘要
PROJECT SUMMARY
The goals of this R01 proposal include the molecular and immunological characterization of vaccine adjuvant
activity associated with processes mediated by the protein Stimulator of Interferon Genes (STING). Two vital
insufficiencies are currently evident regarding adjuvanted human vaccines. First, very few adjuvants are
approved for clinical use in the U.S. Second, the precise mechanistic bases of adjuvant-associated immune
augmentation are poorly understood. Effective adjuvants trigger rapid, localized innate immune responses
following their administration. Fundamentally, the innate signaling is initiated through engagement of pattern
recognition receptors (PRRs) by ligands indicative or imitative of microbial infection. This, in turn, leads to
expression of immunomodulatory and proinflammatory factors that ultimately direct adaptive immune responses
capable of eliminating infected tissues. STING represents the PRR that senses cyclic dinucleotides (CDN), a
product of the cellular enzyme cyclic GMP-AMP synthase (cGAS) following its detection of cytoplasmic dsDNA
derived from microbes, mitochondria, or the nucleus. STING-mediated phenotypes are ultimately conferred by
genes that are transcriptionally induced by the activated protein. This crucially involves the transcription factors
IFN regulatory factor 3 (IRF3) and nuclear factor κB (NF-κB), which synthesize mRNAs of distinct ontologies yet
whose functional roles are mostly unexplored. Moreover, STING appears to control physiological processes that
differ dramatically between cell types of the immune system including stromal, myeloid, and T cells. Intriguingly,
pharmacologic induction of STING-dependent activity in murine models greatly enhances vaccine efficacy as
indicated by protective immunity elicited against diverse pathogens. Unfortunately, the precise molecular and
innate correlates of adaptive immune potentiation associated with STING activity remain largely unexamined.
Furthermore, whether STING adjuvants elicit similarly effective immunogenic outcomes in primates has not been
examined. We plan to couple these with our powerful CRISPR and transcriptomic technologies to obtain
penetrative insight into the fundamental bases of STING-mediated immune outcomes. We hypothesize that the
enhancement of antigen-directed adaptive immunity associated with STING-based adjuvants is functionally
linked to molecular and cellular processes that are discernable using these models. We have also identified a
first-in-class small molecule that activates cGAS-STING across species and enhances immunogenicity to Zika
virus antigen. Including this alongside CDN in in vitro, murine, and nonhuman primate (NHP) models will allow
us to: 1) Validate and characterize cGAS as a new immunotherapeutic target; 2) Demonstrate STING adjuvant
efficacy in a highly clinically relevant model species; and 3) Identify species-specific similarities and differences
with respect to STING-mediated immune responses.
项目摘要
该R 01提案的目标包括疫苗佐剂的分子和免疫学表征
与干扰素基因刺激因子(STING)蛋白介导的过程相关的活性。两个重要
目前关于含佐剂的人疫苗的不确定性是明显的。首先,很少有佐剂
第二,促排剂相关免疫的确切机制基础,
增强的理解很少。有效的佐剂触发快速、局部的先天免疫应答
在他们的管理之后。从根本上说,先天信号是通过参与模式启动的,
通过指示或模拟微生物感染的配体识别受体(PRR)。这反过来又导致了
最终指导适应性免疫应答的免疫调节和促炎因子的表达
能够清除受感染的组织。STING代表感测环状二核苷酸(CDN)的PRR,
细胞酶环GMP-AMP合酶(cGAS)在检测到细胞质dsDNA后的产物
来源于微生物、线粒体或细胞核。STING介导的表型最终由
由活化的蛋白质转录诱导的基因。这关键地涉及转录因子
IFN调节因子3(IRF 3)和核因子κB(NF-κB),它们合成不同本体的mRNA,但它们的表达水平不同。
其功能性作用大多未被探索。此外,STING似乎控制生理过程,
在免疫系统的细胞类型之间存在显著差异,包括基质细胞、骨髓细胞和T细胞。有趣的是,
小鼠模型中STING依赖性活性的药理学诱导大大增强了疫苗功效,
由针对不同病原体引起的保护性免疫指示。不幸的是,精确的分子和
与STING活性相关的适应性免疫增强的先天相关性在很大程度上仍未得到检验。
此外,STING佐剂是否在灵长类动物中引发类似有效的免疫原性结果还没有被证实。
考察我们计划将这些与我们强大的CRISPR和转录组技术结合起来,
深入了解STING介导的免疫结果的基本基础。我们假设
与基于STING的佐剂相关的抗原导向的适应性免疫的增强在功能上是
与分子和细胞的过程联系起来,这些过程可以用这些模型来识别。我们还发现了一个
第一个在物种间激活cGAS-STING并增强Zika免疫原性的小分子
病毒抗原在体外、鼠和非人灵长类动物(NHP)模型中将其与CDN一起包括在内,
我们要:1)鉴定和表征cGAS作为新的免疫靶点; 2)证明STING佐剂
在高度临床相关的模型物种中的功效;以及3)识别物种特异性的相似性和差异
关于针刺介导的免疫反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VICTOR Robert DEFILIPPIS其他文献
VICTOR Robert DEFILIPPIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VICTOR Robert DEFILIPPIS', 18)}}的其他基金
A Self-Adjuvanting Virus Like Particle Vaccine Platform for Emerging Viruses
针对新兴病毒的自我佐剂病毒样颗粒疫苗平台
- 批准号:
10711617 - 财政年份:2023
- 资助金额:
$ 78.71万 - 项目类别:
Anti-tumor efficacy of novel cGAS-STING pathway agonists
新型 cGAS-STING 通路激动剂的抗肿瘤功效
- 批准号:
10286612 - 财政年份:2021
- 资助金额:
$ 78.71万 - 项目类别:
Anti-tumor efficacy of novel cGAS-STING pathway agonists
新型 cGAS-STING 通路激动剂的抗肿瘤功效
- 批准号:
10430274 - 财政年份:2021
- 资助金额:
$ 78.71万 - 项目类别:
Mechanistic Exploration of cGAS-STING-Mediated Vaccine Enhancement
cGAS-STING 介导的疫苗增强机制探索
- 批准号:
10534676 - 财政年份:2019
- 资助金额:
$ 78.71万 - 项目类别:
THE ROLE OF CYTOMEGALOVIRUS PHOSPHOPROTEIN 65 IN VIRUS REPLICATON IN VIVO
巨细胞病毒磷酸蛋白65在体内病毒复制中的作用
- 批准号:
7958465 - 财政年份:2009
- 资助金额:
$ 78.71万 - 项目类别:
THE ROLE OF CYTOMEGALOVIRUS PHOSPHOPROTEIN 65 IN VIRUS REPLICATON IN VIVO
巨细胞病毒磷酸蛋白65在体内病毒复制中的作用
- 批准号:
7715956 - 财政年份:2008
- 资助金额:
$ 78.71万 - 项目类别:
THE ROLE OF CYTOMEGALOVIRUS PHOSPHOPROTEIN 65 IN VIRUS REPLICATON IN VIVO
巨细胞病毒磷酸蛋白65在体内病毒复制中的作用
- 批准号:
7561989 - 财政年份:2007
- 资助金额:
$ 78.71万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 78.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 78.71万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 78.71万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 78.71万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 78.71万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 78.71万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 78.71万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 78.71万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 78.71万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 78.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)